| Q64969067 | A case study of a long-term glioblastoma survivor with unmethylated MGMT and hypermutated genotype. |
| Q90228006 | Accounting for proximal variants improves neoantigen prediction |
| Q90648467 | Actively personalized vaccination trial for newly diagnosed glioblastoma |
| Q47569046 | Advances in immunotherapeutic research for glioma therapy. |
| Q39243060 | Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma |
| Q64090740 | Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer |
| Q64087356 | BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer |
| Q47304287 | Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastomas |
| Q39181810 | Biomarkers and Immunotherapeutic Targets in Glioblastoma |
| Q38847147 | Cancer Immunogenomics: Computational Neoantigen Identification and Vaccine Design. |
| Q64254749 | Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma |
| Q38635512 | Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma |
| Q90730544 | Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma |
| Q64267591 | Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma |
| Q42696942 | ClonEvol: clonal ordering and visualization in cancer sequencing |
| Q47621538 | Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. |
| Q46592106 | Comprehensive Analysis of Hypermutation in Human Cancer |
| Q46037449 | Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. |
| Q55457323 | Current state of immunotherapy for glioblastoma. |
| Q39384263 | DNA Damage and Repair Biomarkers of Immunotherapy Response |
| Q57486475 | Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time |
| Q64268794 | Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma |
| Q55025484 | Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair. |
| Q55457095 | Durable Complete Responses in Some Recurrent High Grade Glioma Patients Treated with Toca 511 & Toca FC. |
| Q92839701 | Effects of ASPP2 on proliferation and apoptosis of malignant spinal tumor cells |
| Q52674249 | Exome analysis of carotid body tumor. |
| Q91734249 | Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype |
| Q49911660 | Functional Analysis of Cancer-Associated DNA Polymerase ε Variants in Saccharomyces cerevisiae |
| Q92179996 | Genomic correlates of response to immune checkpoint blockade |
| Q38676440 | Genomic landscape of high-grade meningiomas. |
| Q92830555 | Genomics-Enabled Precision Medicine for Cancer |
| Q58110826 | Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma |
| Q64110950 | Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma |
| Q89767107 | Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas |
| Q94365704 | Highlights from the Literature |
| Q90399651 | Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations |
| Q38743793 | Immune Checkpoint Inhibitors in Gliomas. |
| Q47915209 | Immunotherapies for malignant glioma. |
| Q90623091 | Immunotherapy Against Gliomas: is the Breakthrough Near? |
| Q47555498 | Immunotherapy for brain tumors: understanding early successes and limitations |
| Q90640719 | Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens |
| Q90661815 | Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome |
| Q64252479 | Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer |
| Q56886821 | Mechanisms of Resistance to Immune Checkpoint Blockade |
| Q92267431 | Mechanisms of immunotherapy resistance: lessons from glioblastoma |
| Q92799371 | Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma |
| Q58107960 | Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer |
| Q97543564 | Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma |
| Q90472252 | Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors |
| Q57060417 | N2M2 (NOA20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma |
| Q62745893 | Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma |
| Q47221163 | Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy? |
| Q58543063 | Novel POLE pathogenic germline variant in a family with multiple primary tumors results in distinct mutational signatures |
| Q63383798 | PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer |
| Q47140563 | PD-1 inhibitors in endometrial cancer |
| Q55277238 | Pediatric High Grade Gliomas in the Context of Cancer Predisposition Syndromes. |
| Q90175028 | Pleomorphic xanthoastrocytoma: a brief review |
| Q47701712 | Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer |
| Q55456776 | Precision Neuro-oncology: the Role of Genomic Testing in the Management of Adult and Pediatric Gliomas. |
| Q57176314 | Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma |
| Q45999303 | Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma. |
| Q96432088 | Prostate carcinogenesis: inflammatory storms |
| Q57798069 | RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma |
| Q60914597 | Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy? |
| Q39421725 | Replicative DNA polymerase defects in human cancers: Consequences, mechanisms, and implications for therapy |
| Q92881504 | Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma |
| Q38373829 | SOX2 immunity and tissue resident memory in children and young adults with glioma |
| Q42745976 | Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next? |
| Q97543552 | TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors |
| Q90707206 | Targeting DNA repair in cancer: current state and novel approaches |
| Q50130464 | Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications. |
| Q61800092 | Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities |
| Q49922510 | Temozolomide-associated Hypermutation in Gliomas |
| Q58119182 | The DNA damage response in immunotherapy and radiation |
| Q61449923 | The Prognostic and Therapeutic Value of PD-L1 in Glioma |
| Q89684724 | The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas |
| Q91728273 | Therapeutic implications of germline genetic findings in cancer |
| Q90057920 | Treatment of an Aggressive Orthotopic Murine Glioblastoma Model with Combination Checkpoint Blockade and a Multivalent Neoantigen Vaccine |
| Q46410671 | Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. |
| Q90273707 | Tumor mutational burden is associated with poor outcomes in diffuse glioma |
| Q92452822 | Tumoral and immune heterogeneity in an anti-PD-1-responsive glioblastoma: a case study |
| Q50112440 | Tumour heterogeneity and resistance to cancer therapies |
| Q49865882 | Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy |
| Q52623832 | Vaccine Strategies in Gliomas. |
| Q63246502 | Virus-Based Immunotherapy of Glioblastoma |